Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose combination of four active pharmaceutical ingredients—ropivacaine (a long-acting amide local anesthetic), epinephrine (a vasoconstrictor), ketorolac (a nonsteroidal anti-inflammatory drug), and clonidine (an alpha-2 adrenergic agonist)—formulated as a ready-to-use injectable solution for periarticular or local infiltration. This multimodal, opioid-sparing analgesic cocktail is used primarily for postoperative pain management in orthopedic and spine surgeries such as lumbar decompression, laminectomy, diskectomy, and arthroplasty. - **Ropivacaine** blocks voltage-gated sodium channels on neuronal membranes to inhibit nerve impulse transmission and provide regional anesthesia. - **Epinephrine** induces vasoconstriction at the injection site to prolong anesthetic effect by reducing systemic absorption of ropivacaine. - **Ketorolac** inhibits cyclooxygenase enzymes (COX-1/COX-2) to reduce prostaglandin synthesis and inflammation-related pain. - **Clonidine** acts on alpha-2 adrenergic receptors to enhance analgesia via both central and peripheral mechanisms; it also prolongs nerve blockade duration when combined with local anesthetics[1][4][6][7]. The combination has demonstrated efficacy in reducing postoperative opioid consumption, lowering pain scores, shortening hospital stays after surgery, and facilitating earlier mobility[1][4][6]. It is available as a patented ready-to-administer formulation under the name R.E.C.K.[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + epinephrine + ketorolac + clonidine.